Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification

Endometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC patients. High-potency progestogens remain the sole therapeutic option recommended by international guidelines for this patient population; however, approximately 30% of patients exhibit no response to such treatment. The concept of EC molecular subtyping, proposed by The Cancer Genome Atlas (TCGA) in 2013, has revolut

Trial Details

NCT ID
NCT07319429
Phase
PHASE2 / PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • PD1 antibody
  • Medroxyprogesterone Acetate 500 MG
  • Megestrol Acetate 160 MG
  • GnRH agonist and Letrozole
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 18 years and ≤ 45 years;
  • Strong willingness to preserve fertility/uterus: Patients who have fertility requirements and insist on preserving fertility; or patients who have …
  • Newly diagnosed endometrial cancer: Pathologically diagnosed as endometrial cancer via endometrial biopsy, diagnostic dilation and curettage, or hy…
  • Recurrent patients: Patients with endometrial lesions who received conservative treatment previously and developed recurrent endometrial cancer, wi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →